ISSN: 2048-9145

Pharmaceutical Bioprocessing

Photodynamic Therapy Scientific Journals

 Photodynamic therapy (PDT) uses light-activated drugs to treat diseases starting from cancer to age-related degeneration and antibiotic-resistant infections. This paper reviews this status of PDT with a stress on the contributions of physics, biophysics and technology, and thus the challenges remaining within the optimization and adoption of this treatment modality. A theme of the review is the complexity of PDT dosimetry due to the dynamic nature of the three essential components—light, photosensitizer and oxygen. Considerable progress has been made in understanding the matter and in developing instruments to live all three, in order that optimization of individual PDT treatments is becoming a feasible target. The final section of the review introduces some new frontiers of research including low rate (metronomic) PDT, two-photon PDT, activatable PDT molecular beacons and nanoparticle-based PDT. Photodynamic therapy (PDT) may be a two-stage treatment that mixes light energy with a drug (photosensitizer) designed to destroy cancerous and precancerous cells after light activation. Photosensitizers are activated by a specific wavelength of light energy, usually from a laser. Photodynamic therapy treats premalignant growths by using special drugs called photosensitizing agents, along side light, to kill pre-cancerous cells. The drugs only work after being activated by certain wavelengths of sunshine . The process also is known as PDT, photo radiation therapy, phototherapy and photo chemotherapy. Most patients are ready to their normal activities 24-48 hours after photodynamic therapy. Avoiding direct sunlight for the first 1 to 2 days in crucial to avoiding getting an exuberant (red) response.  

High Impact List of Articles

Relevant Topics in Clinical